Lord, Abbett & Co
ARRY

Lord, Abbett & Co’s Array Biopharma Inc ARRY Stock Holding History

Lord, Abbett & Co’s Portfolio ARRY Stock Details ARRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-901,813
Closed -$22M – 848
2019
Q1 		$22M Buy
+901,813
New +$18.8M 0.07% 392
2015
Q3 		– Sell
-14,300
Closed -$103K – 992
2015
Q2 		$103K Buy
+14,300
New +$106K ﹤0.01% 916
2013
Q4 		– Sell
-1,349,084
Closed -$8.39M – 1119
2013
Q3 		$8.39M Buy
1,349,084
+880,285
+188% +$5.23M 0.02% 679
2013
Q2 		$2.13M Buy
+468,799
New +$2.52M ﹤0.01% 944

Other funds holding ARRY

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Lord, Abbett & Co's ARRY Position: Q2 2019 in Review

Lord, Abbett & Co sold out of Array Biopharma Inc (ARRY) in Q2 2019, closing a stake of 901,813 shares — an estimated $22M sold.

Lord, Abbett & Co first reported a position in ARRY in Q2 2013 and held it in 4 quarters. The position peaked at $22M in Q1 2019. 319 funds tracked by Wall St. Rank hold ARRY as of Q2 2019.

  • Lord, Abbett & Co reported no remaining Array Biopharma Inc position as of Q2 2019 after selling out during the quarter.
  • Lord, Abbett & Co sold 901,813 Array Biopharma Inc shares in Q2 2019, an estimated $22M.
  • Lord, Abbett & Co first reported a position in Array Biopharma Inc in Q2 2013 and held it in 4 quarters.
  • Lord, Abbett & Co's Array Biopharma Inc position peaked at $22M in Q1 2019.
  • 319 funds tracked by Wall St. Rank held Array Biopharma Inc as of Q2 2019.

Based on Lord, Abbett & Co's 13F filing for Q2 2019, filed 14 Aug 2019.